1. Home
  2. FTV vs VTRS Comparison

FTV vs VTRS Comparison

Compare FTV & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortive Corporation

FTV

Fortive Corporation

HOLD

Current Price

$55.06

Market Cap

17.7B

Sector

Industrials

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$12.89

Market Cap

14.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTV
VTRS
Founded
2015
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7B
14.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FTV
VTRS
Price
$55.06
$12.89
Analyst Decision
Hold
Hold
Analyst Count
11
6
Target Price
$56.55
$11.50
AVG Volume (30 Days)
3.3M
9.6M
Earning Date
02-04-2026
02-26-2026
Dividend Yield
0.44%
3.73%
EPS Growth
N/A
N/A
EPS
1.75
N/A
Revenue
$6,260,300,000.00
$14,124,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
$1.18
P/E Ratio
$21.31
N/A
Revenue Growth
36.34
N/A
52 Week Low
$46.34
$6.85
52 Week High
$83.32
$13.49

Technical Indicators

Market Signals
Indicator
FTV
VTRS
Relative Strength Index (RSI) 51.05 64.61
Support Level $54.13 $12.68
Resistance Level $56.03 $13.49
Average True Range (ATR) 1.25 0.32
MACD -0.12 -0.00
Stochastic Oscillator 64.27 52.31

Price Performance

Historical Comparison
FTV
VTRS

About FTV Fortive Corporation

Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: